NO20064059L - Albumin fusjonsproteiner - Google Patents

Albumin fusjonsproteiner

Info

Publication number
NO20064059L
NO20064059L NO20064059A NO20064059A NO20064059L NO 20064059 L NO20064059 L NO 20064059L NO 20064059 A NO20064059 A NO 20064059A NO 20064059 A NO20064059 A NO 20064059A NO 20064059 L NO20064059 L NO 20064059L
Authority
NO
Norway
Prior art keywords
vectors
albumin infusion
proteins
fusion proteins
infusion proteins
Prior art date
Application number
NO20064059A
Other languages
English (en)
Inventor
Craig A Rosen
William A Haseltine
Paul A Moore
Jason B Bock
Adam Bell
Yanggu Shi
David Lafleur
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NO20064059L publication Critical patent/NO20064059L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)

Abstract

Foreliggende oppfinnelse omfatter albuminfusjonsproteiner. Nukleinsyremolekyler som koder for albuminfusjonsproteinene ifølge oppfinnelsen omfattes også av oppfinnelsen, og likeså vektorer som inneholder disse nukleinsyrene, vertsceller som er transformert med disse nukleinsyrevektorene og fremgangsmåter for fremstilling av albuminfusjonsproteinene ifølge oppfinnelsen og anvendelse av disse nukleinsyrene, vektorene og/eller vertscellene. I tillegg omfatter foreliggende oppfinnelse farmasøytiske preparater som omfatter albuminfusjonsproteiner og fremgangsmåter for behandling, forebyggelse eller lindring av sykdommer, forstyrrelser eller tilstander ved anvendelse av albuminfusjonsproteiner ifølge oppfinnelsen
NO20064059A 2004-02-09 2006-09-08 Albumin fusjonsproteiner NO20064059L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54227404P 2004-02-09 2004-02-09
US54990104P 2004-03-05 2004-03-05
US55690604P 2004-03-29 2004-03-29
US63660304P 2004-12-17 2004-12-17
PCT/US2005/004041 WO2005077042A2 (en) 2004-02-09 2005-02-09 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
NO20064059L true NO20064059L (no) 2006-11-02

Family

ID=34865403

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064059A NO20064059L (no) 2004-02-09 2006-09-08 Albumin fusjonsproteiner

Country Status (21)

Country Link
US (3) US20070048282A1 (no)
EP (1) EP1729795B1 (no)
JP (2) JP5010923B2 (no)
KR (1) KR101184391B1 (no)
CN (1) CN102816241B (no)
AU (2) AU2005211725B2 (no)
BR (1) BRPI0507026A (no)
CA (1) CA2554089C (no)
CY (1) CY1117401T1 (no)
DK (1) DK1729795T3 (no)
ES (1) ES2567634T3 (no)
HK (1) HK1095087A1 (no)
HU (1) HUE027902T2 (no)
IL (1) IL176894A (no)
MA (1) MA28565B1 (no)
MX (1) MXPA06009072A (no)
NO (1) NO20064059L (no)
NZ (1) NZ548612A (no)
PL (1) PL1729795T3 (no)
SI (1) SI1729795T1 (no)
WO (1) WO2005077042A2 (no)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP1276756A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
ES2545090T3 (es) * 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
WO2004096113A2 (en) * 2003-04-28 2004-11-11 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
AU2006280312A1 (en) * 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1929073A4 (en) * 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
SI1965823T1 (sl) * 2005-11-04 2016-09-30 Glaxosmithkline Llc Corporation Service Company Postopki za dajanje hipoglikemičnih sredstev
US20080280328A1 (en) * 2005-11-18 2008-11-13 Novozymes A/S Glucoamylase Variants
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
US7966746B2 (en) * 2006-04-24 2011-06-28 Medical Instill Technologies, LLC Needle penetrable and laser resealable lyophilization method
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
PE20080840A1 (es) * 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
JP2010503396A (ja) * 2006-09-14 2010-02-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
WO2008052043A2 (en) * 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
US8470332B2 (en) 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
MX2009008230A (es) 2007-01-30 2010-03-08 Epivax Inc Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
AU2008275911A1 (en) * 2007-07-19 2009-01-22 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Self- anchoring MEMS intrafascicular neural electrode
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
WO2009030373A1 (en) * 2007-09-05 2009-03-12 Sanofi-Aventis Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
WO2009116557A1 (ja) * 2008-03-21 2009-09-24 富士フイルム株式会社 薬剤含有組成物
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
JPWO2009144927A1 (ja) * 2008-05-27 2011-10-06 富士フイルム株式会社 薬剤含有組成物
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
EP2398827A2 (en) 2009-02-19 2011-12-28 Glaxo Group Limited Improved anti-tnfr1 polypeptides, antibody variable domains&antagonists
EP2419120A4 (en) * 2009-04-08 2016-01-06 Univ California HUMAN PROTEIN CONCERNS WITH CONTROLLED SERUM PHARMACOKINETICS
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
KR101286721B1 (ko) * 2009-06-05 2013-07-16 한국과학기술연구원 폴리-시스테인 펩티드 융합 재조합 알부민 및 이의 제조방법
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
JP2012532619A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
KR20120063475A (ko) 2009-07-29 2012-06-15 글락소 그룹 리미티드 항-ｔｇｆ-베타 수용체 타입 ⅱ 단일 도메인 항체
US20120263701A1 (en) * 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
AU2010311640B2 (en) 2009-10-27 2015-01-29 Glaxo Group Limited Stable anti-TNFR1 polypeptides, antibody variable domains & antagonists
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
US20120308517A1 (en) 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
CA2790329A1 (en) 2010-02-18 2011-08-25 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
EP3424949A1 (en) 2010-04-13 2019-01-09 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
EP2576615B1 (en) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
CN103096891A (zh) 2010-06-24 2013-05-08 判米德有限公司 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病
WO2012013597A1 (de) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
CN103380143B (zh) 2010-12-22 2016-01-06 百时美施贵宝公司 结合il-23的基于纤连蛋白的支架结构域蛋白质
SG191762A1 (en) 2011-01-06 2013-08-30 Glaxo Group Ltd Ligands that bind tgf-beta receptor ii
JP6043629B2 (ja) * 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
CN103732628B (zh) 2011-03-03 2017-06-23 酵活有限公司 多价杂多聚体骨架设计和构建体
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低減した免疫原性を有するフィブロネクチン結合ドメイン
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT2814840T (lt) 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
WO2013130683A2 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten conjugate compositions and methods of making same
US9603897B2 (en) 2012-03-12 2017-03-28 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apolipoprotein D
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
DK3564258T3 (da) 2012-09-13 2021-06-21 Bristol Myers Squibb Co Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
JP6742729B2 (ja) 2013-03-06 2020-08-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 宿主細胞および使用方法
USRE48805E1 (en) * 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
SI2970464T1 (sl) 2013-03-15 2020-08-31 Glaxosmithkline Intellectual Propety Development Limited Anti-LAG-3 vezavni proteini
US9914770B2 (en) 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
KR102111078B1 (ko) 2013-07-04 2020-05-18 노파르티스 아게 O-만노실트랜스퍼라제 결핍 사상균 세포 및 이의 이용 방법
WO2015023890A1 (en) * 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
CN105377882B (zh) * 2014-03-06 2020-05-05 葛兰素史密斯克莱有限责任公司 宿主细胞和使用方法
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
SG11201700446XA (en) 2014-07-21 2017-02-27 Glykos Finland Oy Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
AU2015301753B2 (en) 2014-08-12 2021-04-08 Massachusetts Institute Of Technology Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3702367B1 (en) 2014-11-25 2024-05-15 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
BR112017012928A2 (pt) 2014-12-19 2018-05-15 Alexion Pharma Inc uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste
WO2016171980A1 (en) 2015-04-24 2016-10-27 Bristol-Myers Squibb Company Polypeptides targeting hiv fusion
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
EP4129327A1 (en) 2015-08-28 2023-02-08 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
KR20180042412A (ko) 2015-09-02 2018-04-25 이뮤텝 에스.에이.에스. 항-lag-3 항체
EP3348635B1 (en) * 2015-09-08 2021-02-17 JCR Pharmaceuticals CO., LTD. Novel human serum albumin mutant
CA2997131C (en) * 2015-09-18 2021-05-25 University Of Miyazaki Long-acting adrenomedullin derivative
CN108884147B (zh) 2015-09-23 2024-02-27 百时美施贵宝公司 结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
CN110452295B (zh) * 2015-11-10 2022-10-11 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
US11123405B2 (en) * 2015-12-23 2021-09-21 The Johns Hopkins University Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions
JP2017165713A (ja) * 2016-03-14 2017-09-21 Ｊｃｒファーマ株式会社 血清アルブミン−２０ｋ成長ホルモン融合タンパク質
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途
WO2019152827A1 (en) * 2018-02-02 2019-08-08 AskGene Pharma, Inc. Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof
MX2020008394A (es) 2018-02-12 2020-09-21 Biontech Rna Pharmaceuticals Gmbh Tratamiento que usa arn que codifica citoquinas.
AU2019271149B2 (en) 2018-05-14 2023-07-13 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
BR112020023160A2 (pt) 2018-05-14 2021-02-02 Werewolf Therapeutics, Inc. polipeptídeos de interleucina 2 ativáveis e métodos de uso destes
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
MX2021000801A (es) 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.
BR112021005907A2 (pt) 2018-09-27 2021-08-10 Xilio Development, Inc. citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
JP2022502037A (ja) 2018-09-28 2022-01-11 マサチューセッツ インスティテュート オブ テクノロジー コラーゲンに局在化される免疫調節分子およびその方法
EP3914289A1 (en) 2019-01-23 2021-12-01 Massachusetts Institute of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
WO2020152367A1 (en) 2019-01-25 2020-07-30 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
JP2022519713A (ja) 2019-02-08 2022-03-24 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー Ｃａｒ操作されたｔ細胞およびサイトカインを含む治療
JP2022525921A (ja) 2019-03-18 2022-05-20 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー 免疫エフェクタ細胞の特異的活性化のためのインターロイキン２受容体（ｉｌ２ｒ）およびインターロイキン２（ｉｌ２）バリアント
WO2020200481A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)
EP3955957A1 (en) 2019-04-15 2022-02-23 Qwixel Therapeutics LLC Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
CN111944036A (zh) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
TW202115105A (zh) 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
RU2714392C1 (ru) * 2019-07-09 2020-02-14 Екатерина Олеговна Кудасова Способ модификации поверхности метилметакрилата стоматологического протеза низкотемпературной газоразрядной плазмой кислорода низкого давления за счет изменения контактного угла смачивания по воде и свободной поверхностной энергии
WO2021030633A1 (en) 2019-08-13 2021-02-18 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists
WO2021058091A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
AU2020384375A1 (en) 2019-11-14 2022-05-26 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
WO2021129945A1 (en) 2019-12-27 2021-07-01 Biontech Cell & Gene Therapies Gmbh In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
WO2021174045A1 (en) 2020-02-28 2021-09-02 Bristol-Myers Squibb Company Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
US20230405046A1 (en) 2020-03-16 2023-12-21 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
WO2021197589A1 (en) 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
JPWO2022030580A1 (no) * 2020-08-06 2022-02-10
KR102467827B1 (ko) * 2020-08-31 2022-11-16 연세대학교 산학협력단 미생물 에어로졸화 과정 중 발생하는 손상 방지 방법
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CN112753846B (zh) * 2021-01-27 2023-08-29 吉林农业大学 一种超持水大豆分离蛋白凝胶及其制备方法
JP2024514364A (ja) 2021-04-12 2024-04-01 ビオンテック・ソシエタス・エウロパエア 緩衝物質を含むｒｎａ組成物ならびにその製造、保存および使用のための方法
BR112023021654A2 (pt) 2021-04-20 2023-12-26 BioNTech SE Vacina contra vírus
BR112023023793A2 (pt) * 2021-05-14 2024-01-30 Antlia Bioscience Inc Peptídeo natriurético tipo b modificado
US11572412B2 (en) 2021-06-04 2023-02-07 Boehringer Ingelheim International Gmbh Anti-SIRP-alpha antibodies
CN113391067B (zh) * 2021-06-16 2023-07-25 军事科学院军事医学研究院军事兽医研究所 抗尼帕病毒g蛋白抗体的间接elisa检测方法
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
AU2021470029A1 (en) 2021-10-21 2024-05-02 BioNTech SE Coronavirus vaccine
CA3234578A1 (en) 2021-10-22 2023-04-27 Advait Vijay Badkar Compositions for administration of different doses of rna
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
WO2023141638A1 (en) * 2022-01-21 2023-07-27 The Methodist Hospital System Methods for vascular regeneration and wound treatment
WO2023165681A1 (en) 2022-03-01 2023-09-07 BioNTech SE Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
WO2023193892A1 (en) 2022-04-05 2023-10-12 BioNTech SE Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
WO2023220597A1 (en) 2022-05-10 2023-11-16 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta reduced-binding agonist
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
WO2024028325A1 (en) 2022-08-01 2024-02-08 BioNTech SE Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
WO2024028445A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
CN115960175A (zh) * 2022-08-08 2023-04-14 江南大学 一种强化乳铁蛋白表达的毕赤酵母及其构建方法与应用
WO2024080304A1 (ja) * 2022-10-11 2024-04-18 Ｊｃｒファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質
JP2024056667A (ja) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2052712T3 (es) 1987-04-09 1994-07-16 Delta Biotechnology Ltd Vector de levadura.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
IL90730A0 (en) 1988-06-24 1990-01-18 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
ZA894792B (en) 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
EP0428615A4 (en) 1988-08-11 1991-11-13 California Biotechnology, Inc. Method for stabilizing heterologous protein expression and vectors for use therein
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
US5667986A (en) * 1989-10-18 1997-09-16 Delta Biotechnology Limited Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9013017D0 (en) 1990-06-11 1990-08-01 Mars Uk Ltd Compounds
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5225341A (en) 1990-07-19 1993-07-06 The Regents Of The University Of California Biologically safe plant transformation system using a ds transposon
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
JPH07108232B2 (ja) 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
CA2108451A1 (en) 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
US5646012A (en) 1991-04-30 1997-07-08 Rhone-Poulenc Rorer S.A. Yeast promoter and use thereof
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
FR2686620B1 (fr) 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
CA2131528C (en) 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
BR9305516A (pt) 1992-06-09 1995-03-01 Hoppe Ag Sistema de trinco e fechadura
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
DK0955062T3 (da) 1992-07-31 2007-09-17 Genentech Inc Vandig formulering indeholdende humant væksthormon
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
DK82893D0 (da) 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5512459A (en) 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK144093D0 (no) * 1993-12-23 1993-12-23 Novo Nordisk As
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en) 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US5623054A (en) 1994-06-23 1997-04-22 The General Hospital Corporation Crucifer AFT proteins and uses thereof
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
WO1999014328A2 (en) 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6110707A (en) 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
WO1997026321A2 (en) 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ATE505485T1 (de) 1996-03-01 2011-04-15 Novo Nordisk As Appetithemmendes peptid, zusammensetzung und verwendung
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
JP2000503860A (ja) 1996-08-02 2000-04-04 ザイモジェネティクス，インコーポレイティド 精巣―特異的インシュリン同族体ポリペプチド
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998011136A1 (en) 1996-09-09 1998-03-19 Novo Nordisk A/S A cDNA AND PEPTIDE WITH RELATION TO CANCER AND WEIGHT LOSS
EP0961832A4 (en) 1996-09-18 2003-02-26 Human Genome Sciences Inc HUMAN TUMOR NECROSIS FACTOR-TYPE RECEPTOR GENES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1306092A3 (en) 1996-11-05 2003-05-07 Eli Lilly & Company Use of GLP-1 and analogs administered peripherally, in regulation of obesity
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2001504105A (ja) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１ペプチドの利用
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
AU5549998A (en) 1997-01-24 1998-08-18 Novo Nordisk A/S Synthetic leader peptide sequences
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
US20030049618A1 (en) * 1997-03-07 2003-03-13 Ruben Steven M. 186 human secreted proteins
US20030175858A1 (en) * 1997-03-07 2003-09-18 Ruben Steven M. 186 human secreted proteins
US20060084082A1 (en) * 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US6420526B1 (en) * 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
US20030065139A1 (en) * 1998-03-19 2003-04-03 Craig A. Rosen Secreted protein hmmbd35
JP2002510193A (ja) * 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
EP0970126B1 (en) 1997-04-14 2001-04-18 Micromet AG Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9713412D0 (en) 1997-06-26 1997-08-27 Delta Biotechnology Ltd Improved protein expression strains
KR20010031713A (ko) 1997-11-03 2001-04-16 벤슨 로버트 에이치. 맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제
JP2002512175A (ja) 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
US7205280B2 (en) * 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
DK1088084T3 (da) * 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-humant serumalbumin fusionsprotein
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
EA003922B1 (ru) 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
AU774555B2 (en) 1999-07-19 2004-07-01 Gpc Biotech Inc. Chimeric polypeptides of serum albumin and uses related thereto
US20020048571A1 (en) * 1999-07-19 2002-04-25 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
EP1276756A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
DE60134403D1 (de) 2000-05-19 2008-07-24 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp-1
JP4480329B2 (ja) 2000-10-20 2010-06-16 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１ペプチドによる冬眠心筋および糖尿病性心筋症の治療
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
CA2716959A1 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
CA2446739A1 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
US20030228298A1 (en) * 2001-09-04 2003-12-11 Mark Nesbit Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
AU2002332041A1 (en) * 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
SG159381A1 (en) * 2001-10-10 2010-03-30 Novo Nordisk As Remodeling and glycoconjugation of peptides
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
EP1458860A2 (en) * 2001-12-21 2004-09-22 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
ES2545090T3 (es) * 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20080167238A1 (en) * 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1494704A1 (en) 2002-04-04 2005-01-12 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
EP1594530A4 (en) * 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
CN1802386B (zh) 2003-06-12 2010-12-15 伊莱利利公司 Glp-1类似物融合蛋白质
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US20070270339A1 (en) * 2004-04-23 2007-11-22 Serono, Inc. Use of GPCR54 Ligands for the Treatment of Infertility
EP1838336A2 (en) 2004-12-24 2007-10-03 Amylin Pharmaceuticals, Inc. Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
US8946149B2 (en) 2005-04-11 2015-02-03 Amylin Pharmaceuticals, Llc Use of exendin and analogs thereof to delay or prevent cardiac remodeling
AU2006280312A1 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP2035450A2 (en) 2006-05-26 2009-03-18 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP2068910A2 (en) 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
JP5005450B2 (ja) * 2007-07-13 2012-08-22 本田技研工業株式会社 燃料給油管の口元内部構造

Also Published As

Publication number Publication date
CA2554089A1 (en) 2005-08-25
MXPA06009072A (es) 2007-03-29
CN102816241A (zh) 2012-12-12
US8143026B2 (en) 2012-03-27
IL176894A (en) 2012-08-30
US20070027306A1 (en) 2007-02-01
HUE027902T2 (en) 2016-11-28
ES2567634T3 (es) 2016-04-25
CY1117401T1 (el) 2017-04-26
AU2005211725A1 (en) 2005-08-25
MA28565B1 (fr) 2007-05-02
NZ548612A (en) 2009-11-27
AU2010227035A1 (en) 2010-11-04
CA2554089C (en) 2013-10-22
KR20070016119A (ko) 2007-02-07
US20070048282A1 (en) 2007-03-01
BRPI0507026A (pt) 2007-04-17
JP5010923B2 (ja) 2012-08-29
EP1729795A4 (en) 2008-05-21
KR101184391B1 (ko) 2013-03-14
US20100093627A1 (en) 2010-04-15
IL176894A0 (en) 2006-12-10
JP2012140448A (ja) 2012-07-26
SI1729795T1 (sl) 2016-04-29
CN102816241B (zh) 2015-07-22
HK1095087A1 (zh) 2007-04-27
DK1729795T3 (en) 2016-04-11
WO2005077042A3 (en) 2006-11-30
PL1729795T3 (pl) 2016-08-31
US7569384B2 (en) 2009-08-04
AU2005211725B2 (en) 2010-07-15
JP5568582B2 (ja) 2014-08-06
EP1729795B1 (en) 2016-02-03
WO2005077042A2 (en) 2005-08-25
EP1729795A2 (en) 2006-12-13
JP2007522806A (ja) 2007-08-16

Similar Documents

Publication Publication Date Title
NO20064059L (no) Albumin fusjonsproteiner
NO20081233L (no) Albumin fusjonsproteiner
MX2009002816A (es) Proteinas de fusion de albumina.
WO2007146038A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
EP1276756A1 (en) Albumin fusion proteins
WO2007092772A3 (en) Protein formulations
BR112014018210A2 (pt) moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada
WO2013003641A3 (en) Serpin fusion polypeptides and methods of use thereof
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
BRPI0411112A (pt) proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
MX357803B (es) Moléculas de ácido nucleico artificiales.
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
EA201690946A1 (ru) Мутанты fgf21 и их применение
NO20052276D0 (no) Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi
WO2004085466A8 (en) Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
EP1896588A4 (en) NOVEL Aβ BINDING PROTEIN, ITS PEPTIDE DERIVATIVES AND USES THEREOF
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
ATE486127T1 (de) Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung
NO20056005L (no) Terapautiske midler
WO2008125222A3 (en) New modulation molecules for an improved regulated expression system

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: HUMAN GENOME SCIENCES INC., US

FC2A Withdrawal, rejection or dismissal of laid open patent application